Keeping you up to dateLatest Clearstate Healthcare Insights postsClearstate Insights is your single source to all our latest healthcare intelligence. From recently published reports offering thought-provoking analysis, to information about new products and services, we will ensure you are always kept informed. Sign up to Clearstate’s newsletter
Europe: precision medicine and access to NGS cancer biomarker testing Precision medicine and access to NGS cancer biomarker… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019 Proportion of cancer biomarker testing done with NGS… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Insights into Europe’s covid-19 testing and technology use 2021-2022: PCR v serology v antigen Europe is shifting its covid-19-approach from pandemic to… Centralised Diagnostics (CEDx) | Covid-19 testing | In-vitro diagnostics | Molecular Diagnostics (MDx) | Europe | IVD Gateway | Molecular Diagnostics (MDx)
2022 healthcare megatrends shaping IVD 2022 healthcare megatrends shaping IVD… In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT) | Asia | Europe | Middle East & Africa | IVD Gateway | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT)
Rapid antigen tests to erode PCR-based molecular covid test market in APAC Emergent covid-19 screening technologies coupled with… Covid-19 testing | Molecular Diagnostics (MDx) | Asia | IVD Gateway | Molecular Diagnostics (MDx)
Molecular diagnostics instrument sales in Asia-Pacific set to normalise as vaccination rates rise Molecular diagnostics (MDX) instrument sales in Asia-Pacific… In-vitro diagnostics | Molecular Diagnostics (MDx) | Asia | IVD Gateway | Molecular Diagnostics (MDx)
Covid-19: Molecular testing capacity expands in Asia-Pacific Molecular diagnostics (MDx) testing capacities and… Covid-19 testing | In-vitro diagnostics | Molecular Diagnostics (MDx) | Asia | IVD Gateway | Molecular Diagnostics (MDx)
Point-of-care vs. lab-based covid-19 testing Covid-19 testing has emerged as a top priority for clinical… In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Asia | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT)
Keeping ahead of infectious diseases in Asia-Pacific with increased testing Our new briefing paper looks at the testing trends in… Covid-19 testing | In-vitro diagnostics | Infectious Diseases Testing Monitor | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Asia | IVD Gateway | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT)
Covid-19: Three purchasing behaviour trends at molecular labs (Asia-Pacific) Download our latest IVD infographic "Covid-19: Three… In-vitro diagnostics | Molecular Diagnostics (MDx) | Asia | IVD Gateway
[On-demand Webinar] Covid-19 Impact: Molecular Diagnostic (MDx) Market EIU Healthcare zooms in on two of the fastest-growing… Covid-19 testing | In-vitro diagnostics | Molecular Diagnostics (MDx) | Asia | Europe | Global | IVD Gateway | Molecular Diagnostics (MDx)
Sign up to our free newsletterThe latest trends and insights into the IVD and Surgical sectors, from our specialists and analysts, delivered directly to your inbox. Sign up to Clearstate’s newsletter today. Sign up now